Emergent BioSolutions and Mount Sinai Health System Announce Initiation of DOD-Funded Clinical Program to Evaluate COVID-19 Human Hyperimmune Globulin (COVID-HIG) Product Candidate for Prophylaxis NYSE:EBS

Press/Media

Period29 Dec 2020

Media coverage

3

Media coverage

  • TitleEmergent BioSolutions and Mount Sinai Health System Announce Initiation of DOD-Funded Clinical Program to Evaluate COVID-19 Human Hyperimmune Globulin (COVID-HIG) Product Candidate for Prophylaxis NYSE:EBS
    Media name/outletMENAFN -Press Releases (English)
    Country/TerritoryJordan
    Date29/12/20
    PersonsJudith Aberg
  • TitleEmergent BioSolutions and Mount Sinai Health System Announce Initiation of DOD-Funded Clinical Program to Evaluate COVID-19 Human Hyperimmune Globulin (COVID-HIG) Product Candidate for Prophylaxis NYSE:EBS
    Media name/outletMENAFN -Press Releases (English)
    Country/TerritoryJordan
    Date29/12/20
    PersonsJudith Aberg
  • TitleEmergent BioSolutions and Mount Sinai Health System Announce Initiation of DOD-Funded Clinical Program to Evaluate COVID-19 Human Hyperimmune Globulin (COVID-HIG) Product Candidate for Prophylaxis NYSE:EBS
    Media name/outletMENAFN -Press Releases (English)
    Country/TerritoryJordan
    Date29/12/20
    PersonsJudith Aberg